AXON Neuroscience Employee Directory
Biotechnology ResearchBratislava, Slovakia11-50 Employees
AXON Neuroscience is a clinical-stage biotechnology company based in Bratislava, Slovakia, focused on developing tau-targeted therapies to prevent and treat Alzheimer’s disease and related neurodegenerative disorders. Founded in 1999 by Prof. Michal Novak, who identified tau as a key driver of Alzheimer’s pathology, the company has built a substantial in-house team dedicated to tau research. Its lead candidate, AADvac1, is an active vaccine targeting pathological tau, and Phase II results showed strong immunogenicity and a favorable safety profile, with biomarker data supporting potential disease modification. Axon plans to advance AADvac1 into two major international platform trials starting in 2026—Alzheimer’s Tau Platform for early Alzheimer’s and a PSP platform trial exploring tauopathies beyond Alzheimer’s. The company’s broader pipeline includes a humanized anti-tau monoclonal antibody (AADvac2) and small-molecule programs aimed at tau aggregation and propagation.